Persistence of the bacterial pathogen Granulibacter bethesdensis in chronic granulomatous disease monocytes and macrophages lacking a functional NADPH oxidase

Journal of Immunology

Volumn 191, Issue 6, 2013, Pages 3297-3307

  Chu, Jessica ^a   Song, Helen H ^a   Zarember, Kol A ^a   Mills, Teresa A ^a   Gallin, John I ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; OXYGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ARTICLE; BACTERIAL GROWTH; BIOSYNTHESIS; BONE MARROW CELL; CELL VIABILITY; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME DEFICIENCY; GRAM NEGATIVE BACTERIUM; GRANULIBACTER BETHESDENSIS; HOST CELL; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MACROPHAGE FUNCTION; MONOCYTE; MONONUCLEAR CELL; NONHUMAN; OXYGEN CONSUMPTION; PHAGOCYTOSIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ACETOBACTERACEAE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; MACROPHAGES; MICROSCOPY, CONFOCAL; MONOCYTES; NADPH OXIDASE;

EID: 84884267210     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300200     Document Type: Article

References (79)

1. Winkelstein, J. A., M. C. Marino, R. B. Johnston, Jr., J. Boyle, J. Curnutte, J. I. Gallin, H. L. Malech, S. M. Holland, H. Ochs, P. Quie, et al. 2000. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine 79: 155-169.
2. Song, E., G. B. Jaishankar, H. Saleh,W. Jithpratuck, R. Sahni, and G. Krishnaswamy. 2011. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin. Mol. Allergy 9: 10.
3. Greenberg, D. E., L. Ding, A. M. Zelazny, F. Stock, A. Wong, V. L. Anderson, G. Miller, D. E. Kleiner, A. R. Tenorio, L. Brinster, et al. 2006. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog. 2: e28.
4. Greenberg, D. E., A. R. Shoffner, A. M. Zelazny, M. E. Fenster, K. A. Zarember, F. Stock, L. Ding, K. R. Marshall-Batty, R. L. Wasserman, D. F. Welch, et al. 2010. Recurrent Granulibacter bethesdensis infections and chronic granulomatous disease. Emerg. Infect. Dis. 16: 1341-1348.
5. López, F. C., F. F. de Luna, M. C. Delgado, I. I. de la Rosa, S. Valdezate, J. A. Nieto, and M. Casal. 2008. Granulibacter bethesdensis isolated in a child patient with chronic granulomatous disease. J. Infect. 57: 275-277.
6. Abdel-Haq, N., S. Savas xan, M. Davis, B. I. Asmar, T. Painter, and H. Salimnia. 2009. Asaia lannaensis bloodstream infection in a child with cancer and bone marrow transplantation. J. Med. Microbiol. 58: 974-976.
7. Alauzet, C., C. Teyssier, E. Jumas-Bilak, A. Gouby, R. Chiron, C. Rabaud, F. Counil, A. Lozniewski, and H. Marchandin. 2010. Gluconobacter as well as Asaia species, newly emerging opportunistic human pathogens among acetic acid bacteria. J. Clin. Microbiol. 48: 3935-3942.
8. Bittar, F., M. Reynaud-Gaubert, P. Thomas, S. Boniface, D. Raoult, and J. M. Rolain. 2008. Acetobacter indonesiensis pneumonia after lung transplant. Emerg. Infect. Dis. 14: 997-998.
9. Gouby, A., C. Teyssier, F. Vecina, H. Marchandin, C. Granolleras, I. Zorgniotti, and E. Jumas-Bilak. 2007. Acetobacter cibinongensis bacteremia in human. Emerg. Infect. Dis. 13: 784-785.
10. Juretschko, S., T. K. Beavers-May, and S. H. Stovall. 2010. Nosocomial infection with Asaia lannensis in two paediatric patients with idiopathic dilated cardiomyopathy. J. Med. Microbiol. 59: 848-852.
11. Snyder, R. W., J. Ruhe, S. Kobrin, A. Wasserstein, C. Doline, I. Nachamkin, and J. H. Lipschutz. 2004. Asaia bogorensis peritonitis identified by 16S ribosomal RNA sequence analysis in a patient receiving peritoneal dialysis. Am. J. Kidney Dis. 44: e15-e17.
12. Tuuminen, T., T. Heinäsmäki, and T. Kerttula. 2006. First report of bacteremia by Asaia bogorensis, in a patient with a history of intravenous-drug abuse. J. Clin. Microbiol. 44: 3048-3050.
13. Zarember, K. A., K. R. Marshall-Batty, A. R. Cruz, J. Chu, M. E. Fenster, A. R. Shoffner, L. S. Rogge, A. R. Whitney, M. Czapiga, H. H. Song, et al. 2012. Innate immunity against Granulibacter bethesdensis, an emerging Gramnegative bacterial pathogen. Infect. Immun. 80: 975-981.
14. Savill, J. S., A. H. Wyllie, J. E. Henson, M. J. Walport, P. M. Henson, and C. Haslett. 1989. Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J. Clin. Invest. 83: 865-875.
15. Fernandez-Boyanapalli, R., K. A. McPhillips, S. C. Frasch, W. J. Janssen, M. C. Dinauer, D. W. Riches, P. M. Henson, A. Byrne, and D. L. Bratton. 2010. Impaired phagocytosis of apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-g in a nitric oxide-dependent manner. J. Immunol. 185: 4030-4041.
16. Brown, J. R., D. Goldblatt, J. Buddle, L. Morton, and A. J. Thrasher. 2003. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J. Leukoc. Biol. 73: 591-599.
17. Zarember, K. A., J. A. Sugui, Y. C. Chang, K. J. Kwon-Chung, and J. I. Gallin. 2007. Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion. J. Immunol. 178: 6367-6373.
18. Lambeth, J. D. 2004. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4: 181-189.
19. Ballabh, P., M. Simm, J. Kumari, C. Califano, Z. Aghai, G. Laborada, C. Sison, and S. Cunningham-Rundles. 2003. Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone. Pediatr. Pulmonol. 35: 392-399.
20. Bruns, T., J. Peter, S. Hagel, A. Herrmann, and A. Stallmach. 2011. The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection. Clin. Exp. Immunol. 164: 346-356.
21. De Rossi, L., K. Gott, N. Horn, K. Hecker, G. Hutschenreuter, and R. Rossaint. 2002. Xenon preserves neutrophil and monocyte function in human whole blood. Can. J. Anaesth. 49: 942-945.
22. Reiss, M., and D. Roos. 1978. Differences in oxygen metabolism of phagocytosing monocytes and neutrophils. J. Clin. Invest. 61: 480-488.
23. Leijh, P. C., C. F. Nathan, M. T. van den Barselaar, and R. van Furth. 1985. Relationship between extracellular stimulation of intracellular killing and oxygen-dependent microbicidal systems of monocytes. Infect. Immun. 47: 502-507.
24. Byrd, T. F., and M. A. Horwitz. 1989. Interferon gamma-activated human monocytes downregulate transferrin receptors and inhibit the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. J. Clin. Invest. 83: 1457-1465.
25. Gyan, B., M. Troye-Blomberg, P. Perlmann, and A. Björkman. 1994. Human monocytes cultured with and without interferon-gamma inhibit Plasmodium falciparum parasite growth in vitro via secretion of reactive nitrogen intermediates. Parasite Immunol. 16: 371-375.
26. Peck, R. 1989. Gamma interferon induces monocyte killing of Listeria monocytogenes by an oxygen-dependent pathway; alpha-or beta-interferons by oxygen-independent pathways. J. Leukoc. Biol. 46: 434-440.
27. Mazzi, P., M. Donini, D. Margotto, F. Wientjes, and S. Dusi. 2004. IFN-gamma induces gp91phox expression in human monocytes via protein kinase Cdependent phosphorylation of PU.1. J. Immunol. 172: 4941-4947.
28. Dusi, S., M. Donini, D. Lissandrini, P. Mazzi, V. D. Bianca, and F. Rossi. 2001. Mechanisms of expression of NADPH oxidase components in human cultured monocytes: role of cytokines and transcriptional regulators involved. Eur. J. Immunol. 31: 929-938.
29. Sechler, J. M., H. L. Malech, C. J. White, and J. I. Gallin. 1988. Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc. Natl. Acad. Sci. USA 85: 4874-4878.
30. Czarniecki, C. W., and G. Sonnenfeld. 1993. Interferon-gamma and resistance to bacterial infections. APMIS 101: 1-17.
31. Ezekowitz, R. A., S. H. Orkin, and P. E. Newburger. 1987. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J. Clin. Invest. 80: 1009-1016.
32. Kuhns, D. B., W. G. Alvord, T. Heller, J. J. Feld, K. M. Pike, B. E. Marciano, G. Uzel, S. S. DeRavin, D. A. Priel, B. P. Soule, et al. 2010. Residual NADPH oxidase and survival in chronic granulomatous disease. N. Engl. J. Med. 363: 2600-2610.
33. Serbina, N. V., T. Jia, T. M. Hohl, and E. G. Pamer. 2008. Monocyte-mediated defense against microbial pathogens. Annu. Rev. Immunol. 26: 421-452.
34. Lacey, D. C., A. Achuthan, A. J. Fleetwood, H. Dinh, J. Roiniotis, G. M. Scholz, M. W. Chang, S. K. Beckman, A. D. Cook, and J. A. Hamilton. 2012. Defining GM-CSF-and macrophage-CSF-dependent macrophage responses by in vitro models. J. Immunol. 188: 5752-5765.
35. Cianciotto, N. P. 2001. Pathogenicity of Legionella pneumophila. Int. J. Med. Microbiol. 291: 331-343.
36. Raupach, B., and S. H. Kaufmann. 2001. Immune responses to intracellular bacteria. Curr. Opin. Immunol. 13: 417-428.
37. Dornand, J., A. Gross, V. Lafont, J. Liautard, J. Oliaro, and J. P. Liautard. 2002. The innate immune response against Brucella in humans. Vet. Microbiol. 90: 383-394.
38. Bylund, J., K. L. MacDonald, K. L. Brown, P. Mydel, L. V. Collins, R. E. Hancock, and D. P. Speert. 2007. Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kappa B. Eur. J. Immunol. 37: 1087-1096.
39. Rahman, F. Z., B. Hayee, R. Chee, A. W. Segal, and A. M. Smith. 2009. Impaired macrophage function following bacterial stimulation in chronic granulomatous disease. Immunology 128: 253-259.
40. Lattimer, G. L., L. V. Rhodes, III, J. S. Salventi, J. P. Galgon, V. Stonebraker, S. Boley, and G. Haas. 1979. The Philadelphia epidemic of Legionnaire's disease: clinical, pulmonary, and serologic findings two years later. Ann. Intern. Med. 90: 522-526.
41. Riska, P. F., and S. Carleton. 2002. Latent tuberculosis: models, mechanisms, and novel prospects for eradication. Semin. Pediatr. Infect. Dis. 13: 263-272.
42. Castaño, M. J., and J. Solera. 2009. Chronic brucellosis and persistence of Brucella melitensis DNA. J. Clin. Microbiol. 47: 2084-2089.
43. Plouffe, J. F., M. F. Para, and K. A. Fuller. 1985. Serum bactericidal activity against Legionella pneumophila. J. Clin. Microbiol. 22: 863-864.
44. Eisenschenk, F. C., J. J. Houle, and E. M. Hoffmann. 1999. Mechanism of serum resistance among Brucella abortus isolates. Vet. Microbiol. 68: 235-244.
45. Edelstein, P. H., B. Hu, F. Higa, and M. A. C. Edelstein. 2003. lvgA, a novel Legionella pneumophila virulence factor. Infect. Immun. 71: 2394-2403.
46. Robey, M., W. O'Connell, and N. P. Cianciotto. 2001. Identification of Legionella pneumophila rcp, a pagP-like gene that confers resistance to cationic antimicrobial peptides and promotes intracellular infection. Infect. Immun. 69: 4276-4286.
47. Maloney, E., D. Stankowska, J. Zhang, M. Fol, Q.-J. Cheng, S. Lun, W. R. Bishai, M. Rajagopalan, D. Chatterjee, and M. V. Madiraju. 2009. The two-domain LysX protein of Mycobacterium tuberculosis is required for production of lysinylated phosphatidylglycerol and resistance to cationic antimicrobial peptides. PLoS Pathog. 5: e1000534.
48. Martínez de Tejada, G., J. Pizarro-Cerdá, E. Moreno, and I. Moriyón. 1995. The outer membranes of Brucella spp. are resistant to bactericidal cationic peptides. Infect. Immun. 63: 3054-3061.
49. Dancey, J. T., K. A. Deubelbeiss, L. A. Harker, and C. A. Finch. 1976. Neutrophil kinetics in man. J. Clin. Invest. 58: 705-715.
50. Whitelaw, D. M. 1966. The intravascular lifespan of monocytes. Blood 28: 455-464.
51. Murphy, J., R. Summer, A. A. Wilson, D. N. Kotton, and A. Fine. 2008. The prolonged life-span of alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 38: 380-385.
52. Buckle, A. M., Y. Jayaram, and N. Hogg. 1990. Colony-stimulating factors and interferon-gamma differentially affect cell surface molecules shared by monocytes and neutrophils. Clin. Exp. Immunol. 81: 339-345.
53. Stephen, S. L., K. Freestone, S. Dunn, M. W. Twigg, S. Homer-Vanniasinkam, J. H. Walker, S. B. Wheatcroft, and S. Ponnambalam. 2010. Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease. Int. J. Hypertens. 2010: 646929.
54. Muzio, M., D. Bosisio, N. Polentarutti, G. D'amico, A. Stoppacciaro, R. Mancinelli, C. van't Veer, G. Penton-Rol, L. P. Ruco, P. Allavena, and A. Mantovani. 2000. Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 164: 5998-6004.
55. Sabroe, I., E. C. Jones, L. R. Usher, M. K. Whyte, and S. K. Dower. 2002. Tolllike receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses. J. Immunol. 168: 4701-4710.
56. McDonald, J. U., M. Rosas, G. D. Brown, S. A. Jones, and P. R. Taylor. 2012. Differential dependencies of monocytes and neutrophils on dectin-1, dectin-2 and complement for the recognition of fungal particles in inflammation. PLoS One 7: e45781.
57. McCoy-Simandle, K., C. R. Stewart, J. Dao, S. DebRoy, O. Rossier, P. J. Bryce, and N. P. Cianciotto. 2011. Legionella pneumophila type II secretion dampens the cytokine response of infected macrophages and epithelia. Infect. Immun. 79: 1984-1997.
58. Payne, N. R., and M. A. Horwitz. 1987. Phagocytosis of Legionella pneumophila is mediated by human monocyte complement receptors. J. Exp. Med. 166: 1377-1389.
59. Horwitz, M. A. 1984. Phagocytosis of the Legionnaires' disease bacterium (Legionella pneumophila) occurs by a novel mechanism: engulfment within a pseudopod coil. Cell 36: 27-33.
60. Kagan, J. C., and C. R. Roy. 2002. Legionella phagosomes intercept vesicular traffic from endoplasmic reticulum exit sites. Nat. Cell Biol. 4: 945-954.
61. Banga, S., P. Gao, X. Shen, V. Fiscus, W.-X. Zong, L. Chen, and Z.-Q. Luo. 2007. Legionella pneumophila inhibits macrophage apoptosis by targeting pro-death members of the Bcl2 protein family. Proc. Natl. Acad. Sci. USA 104: 5121-5126.
62. Saunders, B. M., and W. J. Britton. 2007. Life and death in the granuloma: immunopathology of tuberculosis. Immunol. Cell Biol. 85: 103-111.
63. Sullivan, J. T., E. F. Young, J. R. McCann, and M. Braunstein. 2012. The Mycobacterium tuberculosis SecA2 system subverts phagosome maturation to promote growth in macrophages. Infect. Immun. 80: 996-1006.
64. Velmurugan, K., B. Chen, J. L. Miller, S. Azogue, S. Gurses, T. Hsu, M. Glickman, W. R. Jacobs, Jr., S. A. Porcelli, and V. Briken. 2007. Mycobacterium tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells. PLoS Pathog. 3: e110.
65. Danelishvili, L., J. L. Everman, M. J. McNamara, and L. E. Bermudez. 2011. Inhibition of the plasma-membrane-associated serine protease cathepsin G by Mycobacterium tuberculosis Rv3364c suppresses caspase-1 and pyroptosis in macrophages. Front. Microbiol. 2: 281.
66. Porte, F., A. Naroeni, S. Ouahrani-Bettache, and J.-P. Liautard. 2003. Role of the Brucella suis lipopolysaccharide O antigen in phagosomal genesis and in inhibition of phagosome-lysosome fusion in murine macrophages. Infect. Immun. 71: 1481-1490.
67. Fernandez-Prada, C. M., E. B. Zelazowska, M. Nikolich, T. L. Hadfield, R. M. Roop, II, G. L. Robertson, and D. L. Hoover. 2003. Interactions between Brucella melitensis and human phagocytes: bacterial surface O-polysaccharide inhibits phagocytosis, bacterial killing, and subsequent host cell apoptosis. Infect. Immun. 71: 2110-2119.
68. Davies, J. E. 1957. Chronic brucellosis in general practice. BMJ 2: 1082-1087.
69. Bandyopadhyay, P., and H. M. Steinman. 1998. Legionella pneumophila catalase-peroxidases: cloning of the katB gene and studies of KatB function. J. Bacteriol. 180: 5369-5374.
70. Ginsberg, A. M., and M. Spigelman. 2007. Challenges in tuberculosis drug research and development. Nat. Med. 13: 290-294.
71. Rest, R. F., and D. C. Robertson. 1975. Characterization of the electron transport system in Brucella abortus. J. Bacteriol. 122: 139-144.
72. Plank, L. D., and J. D. Harvey. 1979. Generation time statistics of Escherichia coli B measured by synchronous culture techniques. J. Gen. Microbiol. 115: 69-77.
73. Schwab, J. C., and G. L. Mandell. 1989. The importance of penetration of antimicrobial agents into cells. Infect. Dis. Clin. North Am. 3: 461-467.
74. Gebran, S. J., Y. Yamamoto, C. Newton, T. W. Klein, and H. Friedman. 1994. Inhibition of Legionella pneumophila growth by gamma interferon in permissive A/J mouse macrophages: role of reactive oxygen species, nitric oxide, tryptophan, and iron(III). Infect. Immun. 62: 3197-3205.
75. Nash, T. W., D. M. Libby, and M. A. Horwitz. 1988. IFN-gamma-activated human alveolar macrophages inhibit the intracellular multiplication of Legionella pneumophila. J. Immunol. 140: 3978-3981.
76. Herbst, S., U. E. Schaible, and B. E. Schneider. 2011. Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis. PLoS One 6: e19105.
77. Deng, J. C., K. Tateda, X. Zeng, and T. J. Standiford. 2001. Transient transgenic expression of gamma interferon promotes Legionella pneumophila clearance in immunocompetent hosts. Infect. Immun. 69: 6382-6390.
78. Reljic, R. 2007. IFN-gamma therapy of tuberculosis and related infections. J. Interferon Cytokine Res. 27: 353-364.
79. Fabri, M., S. Stenger, D. M. Shin, J. M. Yuk, P. T. Liu, S. Realegeno, H. M. Lee, S. R. Krutzik, M. Schenk, P. A. Sieling, et al. 2011. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci. Transl. Med. 3: 104ra102.